FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia
The US Food and Drug Administration (FDA) has approved for Ingrezza (valbenazine) capsules developed by Neurocrine Biosciences for the treatment of tardive dyskinesia patients.
Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication, Ingrezza (valbenazine) capsules, for the treatment of adults with tardive dyskinesia. This approval marks Ingrezza as the first drug of its kind, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, specifically approved to address this neurological condition. […]